Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi Oral Immunotherapy in Multi Food Allergic Patients
NCT03181009Phase 2Completed
- Start
- Jul 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in food allergy. Started Jul 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT03181009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03181009.